Приказ основних података о документу

dc.creatorĐuričić, Ivana
dc.creatorCalder, Philip C.
dc.date.accessioned2023-02-09T10:46:39Z
dc.date.available2023-02-09T10:46:39Z
dc.date.issued2023
dc.identifier.issn1545-4304
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/4422
dc.description.abstractThe long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are found in seafood, supplements, and concentrated pharmaceutical preparations. Prospective cohort studies demonstrate an association between higher intakes of EPA+DHA or higher levels of EPA and DHA in the body and lower risk of developing cardiovascular disease (CVD), especially coronary heart disease and myocardial infarction, and of cardiovascular mortality in the general population. The cardioprotective effect of EPA and DHA is due to the beneficial modulation of a number of risk factors for CVD. Some large trials support the use of EPA+DHA (or EPA alone) in high-risk patients, although the evidence is inconsistent. This review presents key studies of EPA and DHA in the primary and secondary prevention of CVD, briefly describes potential mechanisms of action, and discusses recently published RCTs and meta-analyses. Potential adverse aspects of long-chain omega-3 fatty acids in relation to CVD are discussed.
dc.publisherAnnual Reviews Inc
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceAnnual review of pharmacology and toxicology
dc.subjectdocosahexaenoic acid
dc.subjecteicosapentaenoic acid
dc.subjectfish oil
dc.subjectheart disease
dc.subjectomega-3 fatty acid
dc.subjectrisk factor
dc.titlePros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health
dc.typearticle
dc.rights.licenseBY
dc.citation.volume63
dc.citation.spage383
dc.citation.epage406
dc.citation.rankaM21~
dc.identifier.wos000915418300020
dc.identifier.doi10.1146/annurev-pharmtox-051921-090208
dc.identifier.pmid36662586
dc.identifier.scopus2-s2.0-85147045422
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/11823/Pros_and_Cons_pub_2023.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу